Journey Medical (DERM) EBITDA Margin (2020 - 2026)
Journey Medical (DERM) reported EBITDA Margin of 9.37% for Q1 2026, up 1593.0% on a YoY basis from 0.55% in Q1 2025, and down 240.14% quarter-over-quarter from 2.76% in Q4 2025.
Journey Medical (DERM) EBITDA Margin (2020 - 2026) Analysis & Trends
Journey Medical has reported EBITDA Margin for 7 years, with the latest figure at 9.37% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 1593.0% year-over-year to 9.37%; the trailing twelve-month figure through Mar 2026 stood at 9.9% (up 239.0% YoY), and the FY2025 full-year result was 13.21%, up 1115.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 9.37%, down from 2.76% in the prior quarter.
- The five-year high for EBITDA Margin was 112.87% in Q3 2023, with the low at 78.29% in Q1 2023.
- Historically, EBITDA Margin has averaged 16.64% across 5 years, with a median of 19.7% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin surged 17203 bps — and 2024, when it sank 13265 bps.
- Journey Medical's EBITDA Margin stood at 53.75% in 2022, then jumped by 192 bps to 49.37% in 2023, then plunged by 67 bps to 16.4% in 2024, then sank by 117 bps to 2.76% in 2025, then plunged by 240 bps to 9.37% in 2026.
- The last three EBITDA Margin figures came in at 9.37% (Q1 2026), 2.76% (Q4 2025), and 8.98% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Journey Medical | 168.75 Mn | 141.53 Mn | 9.70 Mn | -9.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.37% |
| Dec 31, 2025 | -2.76% |
| Sep 30, 2025 | -8.98% |
| Jun 30, 2025 | -19.16% |
| Mar 31, 2025 | -25.30% |
| Dec 31, 2024 | 16.40% |
| Sep 30, 2024 | -19.78% |
| Jun 30, 2024 | -19.70% |
| Mar 31, 2024 | -77.44% |
| Dec 31, 2023 | 49.37% |
| Sep 30, 2023 | 112.87% |
| Jun 30, 2023 | -44.57% |
| Mar 31, 2023 | -78.29% |
| Dec 31, 2022 | -53.75% |
| Sep 30, 2022 | -59.17% |
| Jun 30, 2022 | -39.05% |
| Mar 31, 2022 | -4.27% |
| Dec 31, 2021 | -51.70% |
| Sep 30, 2021 | -64.49% |
| Jun 30, 2021 | -90.02% |